Drugs / EL219
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07215273 | Feb → Dec 2026 expected | fungal infectious disease | Elion Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EL219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215273 ↗ |
| Known as | SF001 | “Formerly SF001, Now EL219 (Turletricin)” NCT07215273 ↗ |
| Known as | Turletricin | “Formerly SF001, Now EL219 (Turletricin)” NCT07215273 ↗ |